| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_762472a657604385d609715411197df8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 |
| filingDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_083e4b0aad1ef8d0bb4bcf761507353a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27248617c1d3c3af20f87fccbb755341 |
| publicationDate |
2023-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2023024904-A1 |
| titleOfInvention |
Delivery compositions and methods |
| abstract |
Modified cells comprising an exogenous non-cytotoxic therapeutic proteinaceous agent are provided. Non-cytotoxic chimeric polypeptides comprising a lymphocyte lytic granule-secreted protein or a functional fragment thereof and a protein of interest are also provided. Therapeutic compositions, nucleic acid molecules and methods of use related to the modified lymphocytes and chimeric polypeptides of the invention are also provided. |
| priorityDate |
2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |